HER2 Positive Breast Cancers Terminated Phase 2 Trials for Retaspimycin (DB05626)

Also known as: HER2 Positive Breast Cancer

IndicationStatusPhase
DBCOND0066412 (HER2 Positive Breast Cancers)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00817362Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast CancerTreatment